<DOC>
	<DOCNO>NCT02654912</DOCNO>
	<brief_summary>This study design compare effectiveness reactive focal drug administration ( RFDA ) use dihydroartemisinin+piperaquine ( DHAP ) versus reactive focal test treat ( RFTAT ) use artemether+lumefantrine ( AL ) routine process identify eliminate malaria transmission measure achieve zero seropositivity child five Southern Province , Zambia . These two strategy potential candidate expand malaria operational surveillance elimination low malaria transmission area .</brief_summary>
	<brief_title>Community-led Responses Elimination : Controlled Trial Reactive Case Detection Versus Reactive Drug Administration</brief_title>
	<detailed_description>The study cluster randomize control trial design evaluate impact RFDA intervention current standard care impact seropositivity child five year , passive surveillance confirm malaria case incidence , elimination transmission hotspot . It conduct among background population ~130,000 people ~30,000 household 16 health center catchment area across several district Southern Province . The government Zambia pursue malaria elimination national goal accelerate timeline trial help evaluate two treatment-based strategy support malaria elimination . The secondary objective study include : 1 ) . Compare effectiveness RFDA use DHAP RFTAT use AL reduce rapid diagnostic test ( RDT ) confirm malaria incidence passive case detection health facility ; 2 ) . Compare effectiveness RFDA use DHAP RFTAT use AL reduce prevalence malaria prevent re-infection individual receive reactive response ; 3 ) . Compare cost-effectiveness RFDA use DHAP RFTAT use AL reduce burden malaria community ; 4 ) . Measure proportion P. falciparum infection likely attributable importation local transmission use parasite genotyping well define genotype spatial distribution ; 5 ) . Assess utility use serology measure short term change malaria transmission evaluate malaria elimination program ; 6 ) . Assess feasibility use remotely sense malaria risk map identify area higher potential local malaria transmission .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Dihydroartemisinin</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<criteria>anyone exclude consent contraindication manufacturer medication include currently take haloperidol , artane , Phenergan ( Promethazine ) , chlorpromazine , erythromycin , Azithromycin , clarithromycin , Ketoconazole , fluconazole , mefloquine ( prophylaxis ) , lumefantrine ( Coartem ) , quinine , Septrin anyone seriously ill currently take antimalarial medicine allergy artemisinin drug pregnant woman first trim child 3 month age report heart condition</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>malaria</keyword>
	<keyword>elimination</keyword>
	<keyword>surveillance response</keyword>
	<keyword>dihydroartemisinin+piperaquine</keyword>
</DOC>